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a b s t r a c t
Purpose: Africa has low breast cancer incidence rates but high mortality rates from this disease due to
poor survival. Delays in presentation and diagnosis are major determinants of breast cancer survival, but
these have not been comprehensively investigated in Africa.
Methods: MEDLINE, Embase, and Global Health were searched to identify studies reporting on delays in
presentation and/or diagnosis of breast cancer published between January 1, 2000 and May 31, 2016.
Data were synthesized in narrative, tabular, and graphical forms. Meta-analyses were not possible due to
between-study differences in the way delays were reported.
Results: Twenty-one studies were included in the review. Study-speciﬁc average times between symptom
recognition and presentation to a health care provider ranged from less than 1 to 4 months in North
Africa and from less than 3 to greater than 6 months in sub-Saharan Africa. Study-speciﬁc average times
from presentation to diagnosis were less than 1 month in North Africa but ranged from less than 3 to
greater than 6 months in sub-Saharan Africa. Reported reasons for these delays included patient-
mediated (e.g., socioeconomic factors) and health systememediated factors (e.g., referral pathways).
Conclusions: This systematic review revealed marked delays in presentation and diagnosis of breast
cancer in Africa. Identiﬁcation of their drivers is crucial to the development of appropriate control
strategies in the continent.
 2017 International Agency for Research on Cancer; licensee Elsevier.
Introduction
Women in Africa currently have one of the lowest incidence rates
of breast cancerworldwide [1]. However, theburden fromthis cancer
is expected to increasemarkedly in thenextdecades.Agrowingaging
population alone, that is, assuming incidence rates will remain con-
stant, will lead to estimated 119,918 new cases in 2030, a near
doubling in the number of incident cases over 20 years [2]. The in-
crease will be even more marked as incidence rates are likely to rise
due to the adoption by Africanwomen of more westernized lifestyle
proﬁles, particularly reproductive patterns characterized by late age
at ﬁrst full-term pregnancy, lower parity, reduced lifetime, breast-
feeding duration, and increases in postmenopausal weight [3].
Despite breast cancer incidence rates being still relatively low in
Africa, mortality rates from this disease are as high, or higher, than in
high-incidence countries due to poor survival [1]. Furthermore, the
proportion of breast cancer cases and deaths at premenopausal ages is
higher in Africa than in high-income countries (HICs), where disease
incidence is highest, reﬂecting the younger age structure of the con-
tinent’s population and possibly also distinctive risk factors and/or
tumor characteristics. Consequently, breast cancer in Africa dispro-
portionatelyaffectswomen in theprimeof their lives, andhence, it has
particularly marked familial, societal, and economic consequences.
A recent systematic review [4] shows that a high proportion of
breast cancer patients in sub-Saharan Africa (SSA) are diagnosed
with late-stage disease leading to poor survival [5]. Studies from
HICs have shown that delays between onset of symptoms and start
of treatment are main determinants of late-stage presentation and
poor survival [6]. Previous studies have attempted to examine
delays in breast cancer presentation, diagnosis, and treatment in
Africa [5,7], but, to our knowledge, these have not been compre-
hensively investigated across the continent. Knowledge of the
length of time intervals between symptom recognition, presenta-
tion, diagnosis, and start of treatmentdand of the factors that may
inﬂuence themdis the key to the development of strategies to
shorten them. Therefore, we conducted a systematic review to
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investigate delays in presentation and diagnosis of breast cancer in
Africa and their determinants.
Materials and methods
Conceptual framework
Figure 1 depicts a patient’s trajectory from the moment she ﬁrst
notices symptom(s) to the time when treatment starts and the
factors that may affect her journey. In HICs with free universal access
to health care, the delay from a woman ﬁrst noticing potential
symptoms of breast cancer to her presentation to a health care
provider is labeled as “patient delay” as it is essentially driven by
patient-mediated factors. In contrast, the time from ﬁrst medical
consultation to the beginning of deﬁnitive treatment is labeled as
“provider delay” as it is driven predominantly by health system-
emediated factors. However, in many African settings, the picture is
likely to be far more complex as delays in both presentation and
diagnosis are likely to result from a complex interplay between
patient-mediated and health systememediated factors. For
instance, a woman may delay presentation not only because of her
lack of breast cancer awareness but also because of the unavailability
of health care providers in her area of residence. Similarly, a woman
who ﬁrst presents with a suspicious cancer may delay diagnosis due
to fear of its consequences (e.g., mastectomy, death). In this review,
we will consider presentation delays as the time interval from
symptom recognition to presentation to the ﬁrst health care pro-
vider, diagnostic delays as the time interval between presentation
and breast cancer diagnosis, and treatment delays as the time in-
terval between diagnosis and start of cancer treatment. These terms
do not carry any judgment on whether these delays are primarily
induced by patient-mediated or provider-mediated factors.
Search methodology
The Preferred Reporting Items for Systematic Reviews andMeta-
Analyses statement guidelines [8] were followed to select relevant
publicationsondelays inbreast cancer presentation anddiagnosis in
Africa. Articles were eligible for inclusion in the systematic review if
they reported ﬁndings from primary research studies conducted in
Africa; reported ondelays inpresentation and/ordiagnosis of female
breast cancer patients; andwere published between January 1, 2000
and May 31, 2016. No language restrictions were imposed. Relevant
publications were searched in the electronic databases MEDLINE,
Embase, and Global Health. A search strategy using synonyms
(including truncations) and subject headings of the search concepts
“breast cancer,” “late diagnosis,” “Africa,” and “determinants,” and
the Boolean operators “AND” and “OR” was used (Appendix A). All
titles and abstracts were screened to identify potentially eligible
articles and the full text for these retrieved and critically reviewed
articles to assess eligibility and, if eligible, to extract relevant data.
Data extraction
The data extraction from each eligible article was carried out
independently by two reviewers (C.E. and I.d.-S.-S.) using a specif-
ically developed standardized data extraction form. The following
information was extracted: the type of catchment population
(e.g., country, urban, rural, or mixed); the study design (quantitative,
qualitative, mixed); the type of recruitment source (primary,
secondary, or tertiary hospital/clinic) and approach (eligibility
criteria, recruitment period, type of sample: consecutive or conve-
nience, i.e., opportunistic, sample size); patient (e.g., age) and tumor
characteristics (e.g., stage, size, histology, symptoms); source
(e.g., patient, medical records) and timing of collection (e.g., before or
after diagnosis) of data on delays and their reasons; reported times
between symptom recognition, presentation, diagnosis, and start of
treatment; and patient-mediated and health systememediated
factors that might have inﬂuenced them. Disagreements between
the two reviewers were discussed, and a consensus was reached.
Quality assessment of the eligible articles
The quality of the articles included in the review was assessed
independently by the same two reviewers. A standardized quality
assessment form was developed, which included parameters to
assess the potential for selection and information bias as well as the
appropriateness of the analytical methods used, including those for
dealing with potential confounders (Appendix B). The overall
quality score of an article was expressed as the sum of its
Fig. 1. Presentation, diagnostic, and treatment delays in breast cancer. BC ¼ breast cancer; HCP ¼ health care provider.
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parameter-speciﬁc scores, which could range from 0 (lowest) to 30
(highest). The higher the score, the higher the methodological
quality of the article; the lower the score, the more likely its
ﬁndings might have been affected by biases.
Data synthesis
Data were synthesized in narrative, tabular, and graphical forms.
Study-speciﬁcmean (SD) ormedian (range), presentation, diagnosis,
and treatment delays are presented; if only categorical data were
reported in the original publication, we used them to estimate the
median, or a weighted mean, whenever possible. Studies differ
greatly in the way they obtained information on potential reasons
for delays and in the way such data were presented (Appendix C).
Most studies simply presented data in a descriptive way (e.g.,
percentages), but a few used logistic regressionmethods to estimate
crude and/or adjusted odds ratios for delayed presentation,
diagnosis, or treatment for each variable examined, with studies
using different cutoff points to deﬁne such delays (e.g., from 2.2 to
>6 months for delay in presentation and from >2 weeks to
6 months for delays in diagnosis; Appendix C). One study in North
Africa [9] reported on delays but only examined factors associated
with late stage (III/IV) versus early stage at diagnosis; late stage was
taken here as a proxy for delays between symptom recognition and
diagnosis. Findings are shown separately for studies conducted in
North Africa (i.e., in Algeria, Egypt, Libya, Morocco, Sudan, Tunisia,
and Western Sahara) and SSA (i.e., countries in East, Middle, South
and West Africa) as deﬁned by the United Nations [10].
Results
A total of 315 articles (after removal of duplicates) were
identiﬁed through electronic searches and their titles and abstracts
were screened for potential eligibility (Fig. 2). In all, 35 articles were
retrieved for full-text review. Of these, only 21 were eligible for
inclusion in the review: 16 quantitative studies, three qualitative
studies, and two mixed studies (quantitative and qualitative).
Study characteristics
Table 1 summarizes themain characteristics of each participating
study. Of the 18 quantitative andmixed-design studies, 8 (44%) were
Fig. 2. Literature search and study selection.
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Table 1
Main characteristics of the 21 studies included in the review
Author,
year [ref no]
Country
(sample size)
Hospital/clinic,
location
Hospital/
clinic-based
catchment
population*
Recruitment Eligibility criteria Age (y) Tumor characteristics Total
quality
score
(max.
score
¼ 30)
Type of
hospital/
clinicy
Type of
samplez
Timing
ofx
Time period First symptom(s) Late stagek Size (cm) Grade ER
status/
histology
Quantitative studies (n ¼ 16)
North Africa (n ¼ 8)
Ahmed,
2014 [11]
Sudan
(n ¼ 141)
National Cancer
Institute, Wad
Medani city
M (U: 55.6%;
R: 44.4%)
T C Re April 2009
to May 2010
LABC who
attended the
breast clinic
Md: 46
Ra: 25e71
Me: 47
n/a LABC (IIIA:
13.2%; IIIB:
78.5%; IIIC:
8.3%)
n/a I: 2.1%
II: 20.1%
III: 77.8%
ERþ: 70.1%
IDC: 77.1%
14
Aloulou,
2015 [12]
Morocco
(n ¼ 130)
Department of
Radiotherapy,
CHU
Mohammed VI,
Marrakech
(public teaching
hospital)
n/a T C Re Jan 2012
to Jan 2013
Histologically
conﬁrmed BC
Me: 46
Ra: 20e78
Lump: 58.5%;
ulceration: 16.2%;
metastasis: 13.8%;
inﬂammation: 11.5%
T2e
T4: 75%
Me: 3.5 II: 56%
III: 28%
IDC: 90% 14
Benbakhta,
2015 [13]
Morocco
(n ¼ 200)
Department of
Radiotherapy,
National Institute
of Oncology, Rabat
U: 74% T C P Dec 2012
to May 2013
Inclusion: all
female patients
with BC diagnosis
treated at this
institution,
Moroccan
nationality,
provided
written consent.
Exclusion: those
who had started
neoadjuvant
chemotherapy.
Me  SD:
49.1  10.7
Ra: 25e82
Breast lump: 46% III: 43%;
IV: 3%
Me: 4.1 n/a n/a 23
El-Shinawi,
2013 [14]
Egypt
(n ¼ 45)
Ain Shams
University
Hospital
Breast Clinic
M (Greater
Cairo: 63%)
T C P Feb 2010
to Dec 2010
Inclusion:
recently
diagnosed BC
patients (<6 mo).
Exclusion:
patients unaware
of their disease,
recurrence
disease, poor
general health
(289 excluded)
Md  SD:
47  10.2
Me  SD:
48.2  10.2
Painless breast
mass: 57.8%; painful
breast mass: 15.6%
n/a n/a n/a n/a 15
Ermiah,
2012 [15]
Libya
(n ¼ 200)
African Oncology
Institute (NOI),
Sabratha
n/a T C P Jan 1, 2008
to Dec 31, 2009
Female patients
with BC diagnosed
at NOI
Me: 45.4
Ra: 22e75
Lump: 68%; skin
changes: 15.5%;
nipple discharge:
13.5%; systemic:
3.0%
III: 54%;
IV: 11.5%
T1 and T2
(5 cm):
40%;
T3 and
T4: 60%
n/a n/a 19
Landolsi,
2010 [16]
Tunisia
(n ¼ 160)
Dept. of Medical
Oncology, Centre
Hospitalier
Universitaire
Farhat Hached,
Sousse
M (U: 37%;
R: 63%)
T C P Sept 1, 2005e
March 31, 2006
Patients presenting
with a locally
advanced (T3 or T4)
or a metastatic BC
Me: 48
Ra: 27e85
n/a T3: 25%;
T4: 71%;
M1: 24%
Me: 6.3 cm
(range:
3e15 cm)
n/a n/a 18
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Mousa,
2011 [17]
Egypt
(n ¼ 163)
Tanta Cancer
Center,
Gharbiah
province
(the largest
cancer center
in the Nile
delta region)
M (U: 36.8%;
R: 63%)
T C P Dec 2009 to
Nov 2010
Newly
diagnosed
BC cases
Md: 53
Me  SD:
51.6  11.5
Mass: 77.4%; pain:
7.6%; nipple
discharge: 3.1%;
increased breast
size: 2.5%; axillary
mass: 2.5%; other:
6.9%
III and
IV: 60.9%
n/a n/a n/a 25
Stapleton,
2011 [9]
Egypt
(n ¼ 343)
National Cancer
Institute, Cairo
(n ¼ 200) & Tanta
Cancer Center,
Gharbiah
(n ¼ 143)
M T C P July 2007 to
Aug 2008
Inclusion criteria:
females with a
newly diagnosed
or treated BC
between July 2007
and August 2008
recruited from
chemotherapy
outpatient clinics.
Exclusion criteria:
patients
aged <18 y,
pregnant or
lactating,
previous cancer
diagnosis
Me  SD:
49.2  10.9
(early stage)
Me  SD:
49.9  11.0
(late stage)
n/a Late
stage:
46.1%
n/a n/a n/a 23
Sub-Saharan Africa (n ¼ 8)
Clegg-
Lamptey,
2009 [18]
Ghana
(n ¼ 66)
Korle Bu
Teaching
Hospital
n/a T O P Sept 2007 to
July 2008
Newly
diagnosed BC
Md: 43
Ra: 20e84
Me: 44.8
n/a n/a n/a n/a n/a 16
Ezeome,
2010 [19]
Nigeria
(n ¼ 162)
University of
Nigeria
Teaching
Hospital Enugu
n/a T C P June 1999 to
June 2001 and
April 2003 to
May 2005
BC patients
managed at the
Surgical Oncology
unit at the
University of
Nigeria Teaching
Hospital Enugu
who provided
consent
Md: 45
Ra: 21e77
Me: 45.7
n/a III: 40.8%;
IV: 37.5%
n/a n/a n/a 23
Ibrahim,
2012 [20]
Nigeria
(n ¼ 201)
Lagos State
University
Teaching
Hospital
U T C P Jan 2009 to
Dec 2010
All female BC
patients referred
to one of the
general surgery
outpatient clinics
of Lagos State
University
Teaching Hospital
Me: 49.82
(SD: 13.59)
Ra: 23e104
n/a III: 62.7%;
IV: 16.4%
n/a n/a n/a 23
Marcus,
2013 [21]
South
Africa
(n ¼ 103)
Sebokeng
Hospital,
Gauteng
U Level 2 public
regional
hospital
C Re Jan 2007 to
Dec 2010
All patients
presenting at the
breast clinic with
advanced BC (IIB or
higher)
Me: 59
Ra: 34e83
Breast lump: 84.5%;
axillary node
abnormal: 19.4%;
abscess/ulcers: 7.8%;
nipple discharge:
6.8%; pain: 4.9% (not
mutually exclusive)
IIIeIV:
95.1%
n/a n/a n/a 13
(continued on next page)
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Table 1 (continued )
Author,
year [ref no]
Country
(sample size)
Hospital/clinic,
location
Hospital/
clinic-based
catchment
population*
Recruitment Eligibility criteria Age (y) Tumor characteristics Total
quality
score
(max.
score
¼ 30)
Type of
hospital/
clinicy
Type of
samplez
Timing
ofx
Time period First symptom(s) Late stagek Size (cm) Grade ER
status/
histology
Otieno,
2010 [22]
Kenya
(n ¼ 166;
98.8%
females)
Kenyatta
National
Hospital
M T C P Oct 1, 2003 to
31 March, 2006
Inclusion: all (male
and female) patients
who attended the
breast clinic or were
admitted to the
three surgical wards
with advanced BC
(stages III/IV).
Exclusions: patients
with treated or
recurrent BC
Me: 47
Ra: 17e88
Breast lump: 87.3% III/IV: 100% n/a n/a n/a 15
Pace,
2015 [23]
Rwanda
(n ¼ 144)
Butaro and
Rwinkwavu
rural hospitals
R S or T (n/a) C P Nov 2012 to
Feb 2014
Inclusion: women
aged 21 y with
pathologically
conﬁrmed BC.
Exclusions: women
diagnosed
elsewhere >6 mo
without initial
staging
Md: 49 Breast pain: 59% III: 52%;
IV: 24%
n/a n/a n/a 25
Price,
2012 [24]
Cameroon
(n ¼ 50 BC
cases;
includes
other
cancers)
Yaounde General
Hospitaldthe
only one in
the country
to offer
chemotherapy
M T C P July 13, 2010
to Aug 12, 2010
Patients aged 18 y
with primary
invasive BC (98%
with histological
conﬁrmation) and
who received
chemotherapy; 96%
female
Me: 46
Ra: 29e75
n/a n/a n/a n/a n/a 20
Toure,
2013 [25]
Cote d’Ivoire
(n ¼ 350)
University
Hospital of
Treichville,
Abidjan
M T C Re Jan 2008
to Dec 2011
Patients with a
histologically
conﬁrmed
adenocarcinoma of
the breast
Me: 42
Ra: 18e81
Breast lump: 6%;
inﬂammation: 54%;
ulcer: 18%; nipple
blood discharge: 8%;
metastases: 14%
III: 76.3%;
IV: 14.3%
n/a n/a Adenocarcinoma:
100%
19
Quantitative and qualitative studies (n ¼ 2)
Dye, 2010 [26] Ethiopia
(n ¼ 69;
98.1%
females)
Tikur Anbessa
Hospital
M T C P 2008
(1 mo only)
Randomly selected
female and male BC
patients seen at
Tikur Anbessa
Hospital over the
span of 1 mo (similar
characteristics to the
total population).
Patients or their
families were
interviewed.
Me: 44.5 n/a n/a n/a n/a n/a 10
Ly, 2002 [27] Mali (n ¼ 44;
43 females)
Hôpital du
Point-G,
Bamako
M T C P Sep 15, 1998
to Aug 15, 2000
Newly diagnosed
and histologically
conﬁrmed BC
patients (male and
female) seen at the
hematology/
oncology service
Me (SD):
46  19.5
Ra: 25e80
Breast lump: 39%;
breast pain: 39%;
pruritus (itching):
12%; nipple blood
discharge: 6.8%;
ulcer: 4.5%
III: 40.9%;
IV: 45.5%
n/a n/a n/a 7
C.Espina
et
al./
A
nnals
of
Epidem
iology
27
(2017)
659
e
671
664
Qualitative studies (n ¼ 3)
Ekortarl,
2007 [28]
Cameroon
(n ¼ 9 BC
cases; 11
subjects
with other
types of
cancer)
Yaounde
General
Hospital
M T O P n/a Cancer patients who
presented with
advanced disease or
who reappeared at
an advanced stage
after having
abandoned
treatment at the
oncology division
Ra: 34e63 n/a Advanced
BC: 100%
n/a n/a n/a n/a
Mbuka-Ongona,
2012 [29]
Botswana
(n ¼ 11)
Princess
Marina Hospital,
Gaborone
(the only hospital
in the country
with oncology
services)
M T O P 2007 Inclusion: all female
adult BC patients
seen andmanaged at
Princess Marina
Hospital.
Exclusions: aged
<18 y; too ill; or
mentally
incapacitated
Me: 54
Ra: 37e76
Most common:
painless lump;
second most
common: bloody
nipple discharge
Majority
stage III
n/a n/a n/a n/a
Pruitt, 2015 [30] Nigeria
(n ¼ 31)
University
College
Hospital
Ibadan
M T C P July 2011 All female BC
patients seen in the
radiotherapy and
surgery clinics, aged
18 y, regardless of
ethnicity, language,
or stage.
Md: 51
Ra: 28e80
n/a n/a n/a n/a n/a n/a
BC ¼ breast cancer; BSE ¼ breast self-examination; CBE ¼ clinical breast examination; CHU¼ Centre Hospitalier Universitaire; ER ¼ estrogen receptor; IDC¼ invasive ductal carcinoma; IQR ¼ interquartile range; LABC ¼ locally
advanced breast cancer; Md ¼ median; Me ¼ mean; n/a ¼ not reported in the original publication; Ra ¼ range.
* Population-based: urban (U), rural (R), mixed (M) area, or not reported (n/a).
y Primary (P), secondary (S), or tertiary (T) hospital/clinic.
z Opportunistic (O) or consecutive (C) sample of patients.
x Patients recruited prospectively (P) or retrospectively (Re).
k Stages IIIeIV (note: T2 can be staged as III A).
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conducted in North Africa and 10 (56%) in SSA, with their sample
sizes ranging from 44 to 350. In contrast, all three qualitative studies
were conducted in SSA, with sample sizes ranging from 9 to 31. All
studies were hospital-based cross-sectional surveys that relied on
consecutive samples of patients, except for two small qualitative
studies [28,29] that relied on convenience samples. Eligibility was
restricted to women with advanced breast cancer in one study in
North Africa [16] and in four studies (three quantitative [11,21,22]
and one qualitative [28]) in SSA. The large majority of studies
recruited breast cancer patients diagnosed predominantly in the
years 2000e2010, but two studies in North Africa [12,13] and two in
SSA [23,30] included patients diagnosed after 2010, whereas one
study in SSA recruited patients diagnosed before 2000 [27] (Table 1).
The average (mean/median) age at breast cancer diagnosis was in
the 40s in the large majority of studies. Most studies involved
collection of data through structured or semistructured question-
naires, usually administered by the researchers or medical staff
around the time of diagnosis, but four studies were conducted
retrospectively using medical records [11,12,21,25]. Information on
ethnicity was provided in only one study, which stated that its
subjects were all black [29]. Information on tumor stage at diagnosis
was available for seven (88%) studies in North Africa and nine (69%)
in SSA. Among studies with stage information and whose subject
eligibility was not dependent on it, the proportion of patients with
late stage (III/IV) was very high (range: 46%e61% in North Africa;
76%e91% in SSA; Table 1).
Quality scores were low for most quantitative studies (Table 1)
albeit slightly higher for those from North Africa (median ¼ 18.5;
range: 14e25) than for those from SSA (median ¼ 17.5; range:
7e25). Similarly, the quality of the qualitative and mixed-design
studies varied substantially, with three studies presenting more
in-depth qualitative results [26,29,30].
Delays in presentation and diagnosis
The time interval between symptom recognition by the woman
to presentation, that is, to ﬁrst visit to a health care provider, varied
substantially across studies but, overall, it was shorter in North
Africa than in SSA (Table 2; Fig. 3A). Of the ﬁve North African studies
that reported on presentation delays, most yielded median esti-
mates of less than 2.5 months; the only exception was a study in
Libya [15] with a median presentation time of 4 months. Of the ﬁve
studies in SSA that provided estimates of time from symptom
recognition to presentation, only one [19] reported a median time
of less than 2.5months, with the remaining reporting average times
ranging from 3.4 months in Mali [27] to greater than 6 months in
South Africa [21].
Fewer studies in North Africa [13,15,17] and in SSA [19,23,24]
gave estimates of the time between presentation and diagnosis,
or between diagnosis and start of treatment. Nevertheless, the
length of these intervals tended to be shorter than the length of the
corresponding intervals between symptom recognition and pre-
sentation in North Africa (all <1 month) but not in SSA (Fig. 3B).
Five North African studies provided median estimates of the
total delay from symptom recognition to date of breast cancer
diagnosis or start of treatment (Fig. 3C). Two of these studies
recruited only advanced breast cancer cases with average total
delays of 8 [16] and 12 months [11]. Median estimates of the total
delay from symptom recognition to diagnosis for the remaining
three studies ranged from 4 [13] to 8.5months [12]. Five SSA studies
provided average times from presentation to diagnosis or start of
treatment (Fig. 3C), with their estimates ranging from 7.9 months in
Ghana [18] to 15 months in Rwanda [23]; median delays were
known to be greater than 6months for two studies [19,24], but their
exact values could not be estimated. In addition, a small qualitative
study (n ¼ 11) in Botswana reported a median time from ﬁrst
symptom(s) to presentation at the hospital where the diagnosis
was ﬁnally made of 3 years [29].
The number of health care providers visited before the one
where the diagnosis was made was reported by only one study in
North Africa [17] and four in SSA [23,24,26,27], with estimates
ranging from a median of 1.5 in Egypt [17] to greater than 5 in
Rwanda [23]; however, these estimates are not entirely comparable
because traditional and religious healers were included in two of
these studies [24,26].
A few studies examined whether delays were associated with
late stage (III/IV) at diagnosis. The study by Benbakhta et al. [13] in
Morocco reported a 6.81-fold (95% conﬁdence interval [CI],
3.65e12.7) increase in the odds of late stage among patients who
delayed presentation by greater than 64 days relative to those
who presented less than or equal to 64 days of symptom recog-
nition. Similarly, the odds of late stage among patients who
experienced a diagnostic delay of greater than or equal to 50 days
were 1.84 (95% CI, 1.05e3.23) times higher than among those
diagnosed less than 49 days of their ﬁrst presentation to a health
care provider [13]. The study by Mousa et al. [17] in Egypt also
reported an association between late stage and delays in pre-
sentation greater than 3 months (crude odds ratio: 1.99; 95% CI,
1.01e1.99) but not with delays in diagnosis greater than 2 weeks.
In Rwanda, late stage was positively associated with both
presentation (median [range] in months: 2 [1e12] for stages I/II, 5
[1e13] for stage III, and 9 [3e18] for stage IV; P ¼ .09) and
diagnostic delays (4 [2e13] months for stage I/II, 4 [2e10] for
stage III, and 11 [5e28] for stage IV; P ¼ .005) [23].
Factors associated with delays
Appendix C summarizes the reasons most commonly reported
by the quantitative studies in the review for late presentation to the
ﬁrst health care provider. They fell into the following categories:
(1) socioeconomic factors such as low educational level; (2) lack of
breast cancer awareness and poor knowledge of early-detection
methods (e.g., breast self-examination); (3) type of initial symp-
toms: painless, not taken seriously, or hoping they would resolve
soon; (4) fear of the disease, its treatment (e.g., mastectomy) or
death, or of being a burden to the family; (5) belief in traditional
medicine or spiritual cures; (6) ﬁnancial constraints; and (7) poor
access to health care (e.g., living too far away from a health care
provider; lack of transportation). Benbakhta et al. [13] found in
mutually adjusted analysis that a delay in presentation of greater
than or equal to 2.2 months in Morocco was positively associated
with low socioeconomic conditions (e.g., living in a rural area, being
illiterate, being a housewife [vs. being employed], and having low
socioeconomic level) and lack of breast cancer awareness (e.g.,
negative family history of cancer, no knowledge of breast self-
examination) (Appendix C). In contrast, Mousa et al. [17] found
no association between delay in presentation greater than
3 months in Egypt and a woman’s socioeconomic characteristics or
type of symptoms before or after adjustment for potential con-
founders. In South Africa, Marcus et al. [21] found in mutually
adjusted analysis the positive associations with late presentation
(>6 vs. 3e6 months) with increasing age and a previous cancer
diagnosis but not with educational level, marital status, or being
employed/unemployed. A mutually adjusted analysis of data from a
study in Rwanda [23] revealed a four-fold to ﬁve-fold increase in
the odds of late presentation (6 months) for patients with low or
no education and for those who visited a traditional healer ﬁrst but
no independent associations with other socioeconomic factors,
breast cancer awareness, symptom, or health serviceserelated
variables (Appendix C). Overall, the ﬁndings from the qualitative
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Table 2
Time from recognition of potential symptoms of breast cancer to presentation to the ﬁrst health care provider, diagnosis and start of treatment, and number of health care
providers visited
Author, year [ref no] Country (sample size) Time from No. of health care providers
visited before visit to the
one where diagnosis was made
Symptom recognition
to presentation
Presentation to diagnosis Diagnosis to start
of treatment
North Africa
Ahmed, 2014 [11],* Sudan (n ¼ 141) Md: 12 mo; Ra: 2e108 mo n/a n/a
Aloulou, 2015 [12] Morocco (n ¼ 130) Me: 8.47 mo; > 6 mo: 63.1% n/a n/a
Benbakhta, 2015 [13] Morocco (n ¼ 200) Md: 65 days (¼2.17 mo);
IQR: 31e121 days;
Ra: 3e579 days
Md: 20 days (¼0.67 mo);
IQR: 10e40 days;
Ra: 1e433 days
Md: 25 days
(¼0.83 mo);
IQR: 9e42 days;
Ra: 0e368 days
n/a
Md: 50 days (¼1.67 mo); IQR: 29, 77 days;
Ra: 5e535 days
Md: 120 days (4.0 mo); IQR: 81e202 days; Ra: 14e860 days
El-Shinawi, 2013 [14] Morocco (n ¼ 45) <1 mo: 46.7%
1 to <6 mo: 37.8%
6 to <12 mo: 0%
>12 mo: 15.6%
n/a n/a n/a
Ermiah, 2012 [15] Libya (n ¼ 200) Md: 4 mo (max. 24)
<3 mo: 46%
3e6 mo: 14%
>6 mo: 40%
Md: < 1 mo
<1 mo: 84.5%
1e6 mo: 4.5%
>6 mo: 11.0%
n/a n/a
Md: 7.5 mo (max. 25 mo)
<3 mo: 30%
3e6 mo: 14%
>6 mo: 56%
Landolsi, 2010 [16],* Tunisia (n ¼ 160) Mean: 11.6 mo; Md: 8 mo n/a n/a
Mousa, 2011 [17] Egypt (n ¼ 163) Me: 6.2 mo; Md: 2.3 mo Presentation to arrival
at TCC: Me: 6.8 wk;
Md: 2.5 wk
n/a Me: 1.5; Ra: 0e4 (does not mention
traditional or spiritual healers)
Stapleton, 2011 [9] Egypt (n ¼ 343) Md: <1 mo n/a n/a n/a
Sub-Saharan Africa
Clegg-Lamptey, 2009 [18] Ghana (n ¼ 66) Me: 46 wk (¼10.7 mo)
Md: 34 wk (¼7.9 mo)
Ra: 1 wk, 5 y
n/a Previous medical consultation: 39.4%
Ezeome, 2010 [19] Nigeria (n ¼ 162) <1 mo: 26.4%
1e3 mo: 28.3%
>3 to 6 mo: 17.6%
>6 mo: 27.7%
<1 mo: 17%
1e3 mo: 10.6%
>3 to 6 mo: 16%
>6 mo: 56.4%
n/a
<1 mo: 5.6%
1e3 mo: 4.3%
>3 to 6 mo: 17.3%
>6 mo: 72.8%
Ibrahim, 2012 [20] Nigeria (n ¼ 201) Me (SD): 12.12 (5.18) mo
Ra: 1 wk to 96 mo
<1 mo: 4.5%
1e3 mo: 13.9%
>3 to 6 mo: 32.8%
>6 to 12 mo: 30.8%
>12 mo: 17.9%
n/a n/a n/a
Marcus, 2013 [21],* South Africa (n ¼ 103) <3 mo: 17.5%
3e6 mo: 30.1%
>6 mo: 52.4%
n/a n/a n/a
Otieno, 2010 [22],* Kenya (n ¼ 166;
98.8% females)
From ﬁrst symptoms to presentation at Kenyatta
National Hospital (late stage only)
<30 d: 6.62%
31e90 d: 20.4%
>90 d: 73.08%
n/a n/a
Pace, 2015 [23] Rwanda (n ¼ 144) Md: 5 mo (IQR: 1e13) Md: 5 mo (IQR: 2e14) n/a <5 HCP visits: 44%
5 HCP visits: 56% (does not mention
traditional or spiritual healers)
Md: 15 mo (IQR: 8e32)
Price, 2012 [24] Cameroon (n ¼ 50) n/a >3 mo: 42%
>6 mo: 32%
n/a Consulted 4 HCP: 46% (including
traditional and spiritual healers)
>6 mo: 60%
Toure, 2013 [25] Cote d’Ivoire (n ¼ 350) <6 mo: 9.1%
6e10 mo: 12%
10e14 mo: 78.9%
Weighted mean: 10.7 mo
n/a n/a
Quantitative and qualitative studies
Dye, 2010 [26] Ethiopia (n ¼ 69;
98.1% females)
n/a n/a n/a >2 HCP visits: 73.2% (including
traditional or spiritual healers)
(continued on next page)
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studies supported the evidence from the quantitative studies
[26,28e30] (Appendix C).
The reasons given by the patients for delays between
presentation and diagnosis, or start of treatment, included
patient-mediated factors (e.g., socioeconomic factors, type of
symptoms, having tried traditional treatments ﬁrst, ﬁnancial
problems, fear of the disease and/or its treatment, and denial)
and health care provideremediated factors (e.g., travel time to
health care provider, the number and type of health care
providers contacted before diagnosis, delayed referrals or
nonreferrals, misdiagnosis, wrong advice or false reassurances,
delays in obtaining diagnostic conﬁrmation, and in starting
treatment) (Appendix C). The study in Morocco by Benbakhta
et al. [13] found in mutually adjusted analyses that a delay greater
than 1.7 months between presentation and start of treatment was
associated with older age, illiteracy, low socioeconomic level,
distance to health care provider greater than or equal to 100 km,
and greater than or equal to 3 consultations before the diagnostic
one. Mousa et al. [17] in Egypt showed that after adjustment for
potential confounders, the odds of a delay greater than 2 weeks
from the ﬁrst medical consultation to arrival at the diagnostic
center were not associated with the patient’s age, socioeconomic
conditions, or type of symptoms but were strongly associated
with the type of the ﬁrst health care provider visited and the
navigation pathway followed by the patient (Appendix C). In
Rwanda, Pace et al. [23] found in mutually adjusted analyses a
2.69 (95% CI, 1.24, 5.84) higher odds of a delay greater than or
equal to 6 months for patients who visited ﬁve or more health
care facilities before diagnosis but no associations with the
patient’s socioeconomic conditions, reproductive history, or type
of symptoms. In the qualitative studies (Appendix C), some
women reported poor clinical practices (e.g., inadequate
diagnosis by general doctors [28], hospital strikes [30], or having
sought alternative care after receiving the diagnosis).
Discussion
To our knowledge, this is the ﬁrst systematic review of studies
that reported on delays in a woman’s breast cancer journey in
Africa. Its ﬁndings highlighted three main issues. First, there is a
paucity of published data on delays in the presentation and
diagnosis of the most common female cancer in Africa [2]. The
systematic review identiﬁed only 21 published studies over the
16-year period (January 2000 to May 2016), comprising only 2788
breast cancer patients from across the continent (1382 from North
Africa; 1406 from SSA). Second, the ﬁndings revealed marked
delays in presentation and diagnosis of breast cancer patients in
both North Africa and SSA. Third, the reported reasons for such
delays were complex and included both patient-mediated and
health systememediated factors; however, the relative importance
of these two types of factors varied from setting to setting.
There is strong evidence that a delay from symptom recogni-
tion to diagnosis of more than 3 months is associated with later
stage at presentation and poorer survival [6]. This review revealed
substantially longer delays in both North Africa and SSA, with
reported average times from symptoms recognition to diagnosis
between 4 and 15 months. These estimates are in line with those
observed in other low- and middle-income countries (LMICs) (e.g.,
7.6 months in Brazil [31], 5.5 months in Malaysia [32]) but much
higher than those observed in HICs (e.g., 34 days in France [33],
48 days in the United States [34]). The very long time intervals
from symptom recognition to diagnosis in Africa resulted from
delays in both presentation and diagnosis. All studies in this re-
view, with the exception of two [9, 14], reported average presen-
tation intervals between 2.2 months and greater than 6 months,
much longer than those observed in HICs (e.g., 9 days in the United
Kingdom [35]; 16 days in Germany [36]). Similarly, reported
diagnostic intervals in Africa were much longer than those found
in HICs (e.g., from 10 to 42 days in France [33], Germany [37], and
the United States [34]) but similar to what has been described for
other LMICs (e.g., median of 5 months in Brazil [31], Colombia [38],
and Mexico [39]).
As we had hypothesized in our conceptual model, delays in
presentation in Africa were found to be associated not only with
patient-mediated factors (e.g., low educational level, poor breast
cancer awareness, use of alternative care medicine) but also with
health serviceemediated factors (e.g., distance to the nearest health
care center). These results are similar to those from previous
studiesdfor example, being unaware of the warning signs or tests
for breast cancer [5], patients only seeking conventional care when
traditional treatment has failed [40], or inability to afford the costs
Table 2 (continued )
Author, year [ref no] Country (sample size) Time from No. of health care providers
visited before visit to the
one where diagnosis was made
Symptom recognition
to presentation
Presentation to diagnosis Diagnosis to start
of treatment
Ly, 2002 [27] Mali (n ¼ 44;
43 females)
1e12 wk (¼2.8 mo): 63.6%
13 (¼3.0 mo) to 48 wk
(¼11.2 mo): 36.4%
Weighted mean: 3.4 mo
n/a n/a >3 HCP: 50% (only conventional
HCP included)
From symptoms to ﬁrst appointment at the study
(diagnostic) hospital:
Ra: 8 wk (¼1.87 mo) to 72 wk (¼16.8 mo)
Qualitative studies
Ekortarl, 2007 [28] Cameroon
(n ¼ 9 BC cases;
11 subjects
with other
types of cancer)
n/a n/a n/a n/a
Mbuka-Ongona, 2012 [29] Botswana (n ¼ 11) Time from ﬁrst symptom to presentation at
study hospital (PMH):
Me: 3 y; Ra: 1e10 y
n/a n/a
Pruitt, 2015 [30] Nigeria (n ¼ 31) n/a n/a n/a
BC ¼ breast cancer; CI¼ conﬁdence interval; HCP ¼ health care provider; IQR ¼ interquartile range; Md ¼median; Me¼mean; n/a ¼ not reported in the original publication;
Ra ¼ range; TCC ¼ Tanca Cancer Center.
* Study recruited only patients with advanced breast cancer (see Table 1).
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Fig. 3. Study-speciﬁc delays in breast cancer: (A) from symptom recognition by the patient to her presentation to the ﬁrst health care provider; (B) from presentation to breast
cancer diagnosis or start of cancer treatment; and (C) from symptom recognition to diagnosis or start of treatment. aStudy eligibility restricted to advanced BC. See Table 2 for more
detailed information on study-speciﬁc estimates of delay. A dashed line indicates that the delay estimate shown in the ﬁgure is an underestimation of the median value (the latter
could not be calculated from the data provided in the original article). No delay estimates for Otieno et al. [22] are shown because average time from symptoms to diagnosis could
not be estimated (>3 months for 73% of patientsdall with advanced BCdwith no further information provided; see Tables 1 and 2). BC ¼ breast cancer; HCP ¼ health care provider;
IQR ¼ interquartile range; Md ¼ median; Me ¼ mean; SSA ¼ sub-Saharan Africa; wMe ¼ weighted mean.
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of treatment [41]. Similarly, delays in diagnosis in Africa were
inﬂuenced by both patient-mediated factors (e.g., low educational
level, ﬁnancial problems) and health systememediated factors (e.g.,
type of ﬁrst health care provider visited, number of providers
visited before diagnosis, type of navigation pathway followed
before reaching the diagnostic center). A high number of referrals
make the patient’s journey through the health system longer
resulting in a more advanced tumor stage at diagnosis; however, it
is also conceivable that a low number of referrals might reﬂect a
more aggressive tumor, or a longer time interval before presenta-
tion to the ﬁrst health care provider, and thus a more advanced
tumor that was easily identiﬁed by the physician. Of note, however,
is the fact that none of the articles directly examined health system
factors, for example, through interviews with health care providers,
relying instead on patients’ reports.
Strengths and limitations of the review
Major strengths of this review include the systematic search
strategy used to identify eligible English and non-English publi-
cations and the use of standardized methods for data extraction
and synthesis. The review also has weaknesses. Its representa-
tiveness may have been compromised by several factors. First,
publication bias cannot be excluded as gray literature was not
included in this review. Second, the review included studies from
only 4 of 7 North African countries and 11 of 51 SSA countries,
albeit the latter comprised studies from all four SSA regions
(i.e., from Eastern, Western, Southern, and Middle Africa). Third,
none of the studies in the review were population based; they
were all hospital based, predominantly from tertiary hospitals as
these are the only ones in most African countries to have appro-
priate cancer diagnostic and treatment facilities. However, such
studies excluded, by design, the large number of patients who
never reach tertiary hospitals, some of whom are never diagnosed.
Hence, the included patients who reached tertiary facilities are
unlikely to be a representative sample of all breast cancer patients
in Africa.
The methodological quality of most articles was low. In partic-
ular, measurement errors may have affected the validity of the
review’s ﬁndings as although most of the studies recruited women
prospectively, patients were asked to remember the time from ﬁrst
symptom(s) to presentation, and this might have introduced recall
errors and even biases. Little detail was provided in the original
articles on the speciﬁc instruments used to collect information and
the methods used to estimate times to presentation, diagnosis, and
treatment, including on the way questions to patients on time
intervals were formulated and on how relevant time-related events
(e.g., dates of contact with a ﬁrst health care provider, breast cancer
diagnosis, and start of treatment) were deﬁned. Between-study
differences in these methodological issues may have affected
their comparability. When questioned about the reasons for delays,
patients might have been reluctant to admit less orthodox behav-
iors such as the use of traditional medicine. Reassuringly, however,
the studies that examined associations between self-reported
delays and late stage at diagnosis showed, as expected, strong
positive associations. Many studies had relatively small sample
sizes, and thus, their ability to precisely quantify delays and their
power to detect associations were limited. There were large
variations across studies in the way data were analyzed (e.g., only a
few quantitative studies attempted to control for confounders;
none of the qualitative studies conducted theoretical analyses)
and summary ﬁndings presented, hampering between-study
comparisons, and precluding the conduct of meta-analyses.
Conclusions
Several studies in Africa have shown that early-stage breast cancer
is associated with better survival than late-stage disease [42,43],
consistent with early diagnosis and treatment being associated with
reductions in mortality from this disease in the region. The long
Fig. 3. (continued).
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presentation and diagnostic delays identiﬁed by this review indicate
that there is considerable potential to introduce interventions aimed
at shrinking the time intervals between symptom recognition and
diagnosis. Mammography screening is often advocated as the best
intervention to improving early diagnosis of breast cancer, but the
ﬁndings from this review strongly argue against adopting such an
approach in African settings. Screening can only reduce breast cancer
mortality if women with suspicious screen-detected lesions have ac-
cess to appropriate diagnosis and treatment. Despite the limitations of
the existing data, and the high heterogeneity across African settings,
the long diagnostic delays highlighted by the review indicate that the
addition of women with asymptomatic screen-detected tumors
would place signiﬁcant additional burden on most, already over-
stretched, health care systems in the region. Instead, downward-stage
migration of symptomatic breast cancer should be the priority inmost
settings as recommended by the Breast Health Global Initiative and
the Breast Cancer Initiative 2.5 [44]. Achieving this would require
increased breast cancer awareness of the population, enhanced ability
of primary and secondary health care professionals to diagnose breast
cancer, as well as clear patient navigation pathways to facilitate timely
referral and admission of patients to tertiary care services for early
care. The introduction of such an approach in other LMICs has
demonstrated that downward-stage migration of breast cancer is
achievable in the absence of screening [45].
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Appendix A
Examples of the search string used in MEDLINE
1. (breast OR mammary) ADJ3 (neoplasm* OR cancer* OR tumo?r* OR carcinoma)
2. exp Breast Neoplasms
3. 1 OR 2
4. (delay* OR late OR poor) ADJ1 (presentation OR attendance OR diagnosis OR stage OR detection OR prognosis)
5. exp Delayed Diagnosis
6. exp Prognosis
7. exp Early Diagnosis
8. 4 OR 5 OR 6 OR 7
9. (determinant* OR factor* OR reason* OR barrier* OR attitude* OR belie* OR awareness OR knowledge OR fear* OR cultur* OR perception*)
10. (uptake OR utilization OR access OR accept* OR intent* OR distance OR transport* visit* OR presentation*) ADJ3 (health care centre OR hospital OR clinic OR health
service OR doctor OR physician OR mammogram* OR screening OR exam*)
11. exp “Behavior and Behavior Mechanisms”
12. exp Attitude to Health
13. exp Socioeconomic Factors
14. exp Health Status Disparities
15. exp Communication Barriers
16. OR/9-15
17. Africa OR Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon OR Cape Verde OR Central African Republic OR Chad OR Democratic
Republic of the Congo OR Djibouti OR Egypt OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea-Bissau OR Guinea OR Ivory Coast
OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco OR Mozambique OR Namibia OR Niger OR
Nigeria OR Republic of Congo OR Rwanda OR Senegal OR Sierra Leone OR Somalia OR South Africa OR South Sudan OR Sudan OR Swaziland OR Tanzania OR Togo OR
Tunisia OR Uganda OR Zambia OR Zimbabwe
18. exp Africa
19. 17 OR 18
20. 3 AND 8 AND 16 AND 19
Appendix B. Quality assessment of the eligible articles
The quality of the articles included in the review was assessed by
developing a standardized quality assessment form, which included
parameters on three main domains: (1) Selection bias: study design
(score 0 if unclear, 1 if retrospective case series, 2 if prospective
study); study population (score 0 if unclear, 1 if opportunistic
hospital-based study, 2 if consecutive hospital-based study, 3 if
population-based study); restricted to late stage/advanced disease
(score 0 if unclear, 1 if yes, 3 if no); participation rate (score 0 if
unclear, 1 if <70%, 2 if 70%). (2) Information bias: source of the
information (i) for patient-mediated factors (score 0 if unclear or n/a
[not applicable], 1 if medical records, 2 if proxy [relative], 3 if pa-
tient); (ii) for health serviceemediated factors (score 0 if unclear or
n/a, 1 if proxy [relative], 2 if patient, 3 if medical records); timing of
information collection (score 0 if unclear or n/a, 1 if after patient was
aware of her breast cancer diagnosis, 2 if around the time of her
diagnosis, 3 if before her diagnosis); potential of observer/interviewer
bias (score 0 if unclear, 1 if likely, 2 if unlikely as information was
validated against medical records or a previously validated ques-
tionnaire was used). (3) Analytical methods including dealing with
potential confounders: deﬁnition of delays in presentation, diagnosis,
and/or treatment (score 0 if not given, 1 if given but unclear or stage
used as a proxy, 2 if clear); distinction between patient-related and
health systemerelated factors (score 0 if not given, 1 if focus only on
one of these, 2 if given but unclear, 3 if clear); statistical methods
(score 0 if not properly described, 1 if only descriptive, 2 if analytical
or in-depth); adjustment for potential confounders (score 0 if n/a, 1 if
only crude estimates given, 2 if adjusted). The overall quality score of
an article was expressed as the sum of its parameter-speciﬁc scores,
which could range from 0 (lowest) to 30 (highest). The higher the
score, the higher the methodological quality of the article and, hence,
the lower the score, the more likely its ﬁndings might have been
affected by biases.
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Appendix C
Factors associated with delayed presentation and delayed diagnosis or start of treatment of breast cancer in Africa: summary of the ﬁndings reported by the studies included in the review
Author, year [ref no]
(country)
Factors associated with delay between symptoms recognition and ﬁrst visit to an
HCP
Factors associated with delay between ﬁrst visit to an HCP and BC diagnosis or start of treatment
Crude Adjusted Crude Adjusted
North Africa
Ahmed, 2014 [11],y
(Sudan)
Factors associated with late presentation in patients with locally advanced
breast cancer (%)
Lack of education: 39.5%
Financial aspects: 28.6%
Use of traditional medicine: 13.8%
Limited access to medical care: 9%
Ignorance: 6.9%
Fear of being a burden to relatives: 2.7%
n/a
Aloulou, 2015 [12]
(Morocco)
Reasons for delays from symptoms recognition to diagnosis:
Fear of cancer and/or treatment: 4%;
Financial problems: 40%;
Tried traditional treatments: 20%
Health services:
Distance from health center: 23%;
Wrong diagnosis: 6%;
Inadequate medical care: 7%
Benbakhta, 2015 [13]
(Morocco)
Delay from symptoms recognition to
presentation >2.2 mo: OR (95% CI)
Socioeconomic:
Aged >65 versus <45 y: 1.68 (0.64,
4.38)
Rural versus urban area of residence:
4.62 (2.24, 9.52)
Illiteracy versus secondary/university:
4.56 (2.26, 9.18)
Employed versus housewife:
0.23 (0.13, 0.57)
Low versus mid socioeconomic level:
8.55 (3.16, 23.17)
>5 people in household:
2.05 (1.14, 3.69)
BC awareness:
No knowledge versus knowledge of
BSE:
17.88 (8.74, 36.56)
Positive versus negative family history:
2.51 (1.23, 5.13)
Type of symptoms:
Presence of typical versus atypical
symptoms: 0.75 (0.33, 1.67)
Health services related:
Distance from HCP of presentation
100 versus <100 km: 8.62 (1.01,
67.14)
Delay from symptoms recognition to
presentation >2.2 mo:
OR* (95% CI)
Socioeconomic:
Rural versus urban area of residence:
3.00 (1.24, 7.23)
Illiteracy versus secondary/university:
4.90 (2.50, 6.30)
Employed versus housewife:
0.1 (0.03, 0.47)
Low versus mid socioeconomic level:
7.60 (2.24, 25.77)
BC awareness:
No knowledge versus knowledge of
BSE: 11.51 (5.18, 25.57)
Negative versus positive family history:
2.11 (1.10, 4.16)
*Mutually adjusted
Delay between presentation and start of
treatment >1.7 mo: OR (95% CI)
Socioeconomic:
Aged >65 versus <45 y: 1.94 (1.36, 2.40)
Rural versus urban area of residence: 2.10 (1.18,
4.40)
Illiteracy versus secondary/university: 2.70
(1.38, 5.27)
Low versusmid socioeconomic level: 2.61 (1.20,
23.17)
Health services:
Distance to HCP of diagnosis >100 versus
<100 km: 2.46 (1.26, 5.20)
3 versus <3 consultations before diagnostic
one: 11.44 (4.83, 27.08)
Delay between presentation and start of
treatment ‡1.7 mo: OR* (95% CI)
Socioeconomic:
Aged >65 versus <45 y: 2.51
(1.50, 11.42)
Illiteracy versus secondary/university: 1.40 (1.12,
6.50)
Low versus mid socioeconomic level: 2.59 (1.04,
6.50)
Health services:
Distance to HCP of diagnosis 100 versus 100 km:
2.58 (1.12, 3.56)
3 versus <3 consultations before diagnostic one:
11.27 (4.12, 28.34)
*Mutually adjusted
El-Shinawi, 2013 [14]
(Egypt)
Delay from symptoms recognition to
presentation to an HCP
BC awareness:
n/a n/a n/a
(continued on next page)
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Appendix C (continued )
Author, year [ref no]
(country)
Factors associated with delay between symptoms recognition and ﬁrst visit to an
HCP
Factors associated with delay between ﬁrst visit to an HCP and BC diagnosis or start of treatment
Crude Adjusted Crude Adjusted
Higher awareness of BSE associated
with less delay in seeking medical
advice (2.9 þ 2.3 mo) relative to low
awareness
(15.5 þ 22.6 mo) (P ¼ .04)
Ermiah, 2012 [15]
(Lybia)
Delay from symptom recognition to diagnosis >3 mo
Socioeconomic:
Aged 50 versus <50 y:
64% versus 51% (P[ .033)
Single versus married: 52% versus 56% (P ¼ .6)
Housewife versus employed: 61% versus 48% (P ¼ .09)
Illiteracy versus literacy: 69% versus 38% (P [ .009)
Reproductive:
Postmenopausal versus premenopausal: 64%
versus 50% (P ¼ .05)
No versus breastfeeding: 38% versus 58.6% (P ¼ .09)
OC use >5 y versus <5 y or no use:
86% versus 53% (P [ .04)
BC awareness:
Positive versus negative family history:
45% versus 57% (P ¼ .3)
Positive versus negative history of benign
breast disease: 73% versus 52% (P [ .03)
Knowledge of BSE versus no knowledge:
0% versus 58% (P < .0001)
Type of symptoms:
Initial symptom being a lump versus being
other symptoms: 41% versus 86% (P < .0001)
Landolsi, 2010 [16],y
(Tunisia)
Delay from symptoms recognition to presentation at study setting, i.e., to diagnosis
93% delay related to personal reasons:
Not aware of disease: 35%
Not having practiced BSE: 23.5%
Fear of cancer and/or treatment: 14%
Financial problems: 14%
Others: 13.5%
24% delay related to health services:
Wrong reassurance: 47.5%
Misdiagnosis: 18%
Mousa, 2011 [17]
(Egypt)
Delay from symptoms recognition to
ﬁrst medical
consultation >3 mo: OR (95% CI)
Socioeconomic:
Aged 50 versus
< 50 y: 1.1; 95% CI: 0.6, 2.1
Urban versus rural residence:
1.3; 95% CI: 0.7, 2.6
Bachelor versus < bachelor
education: 0.6 (0.3, 1.2)
Type of symptoms:
Breast mass versus other ﬁrst
symptom: 2.1 (0.9, 4.8)
Delay from symptoms recognition to
ﬁrst medical
consultation >3 mo: OR* (95% CI)
Socioeconomic:
Aged 50 versus < 50 y: 0.9 (0.4, 1.9)
Urban versus rural residence: 1.4 (0.7,
2.9)
Bachelor versus <bachelor education:
0.6 (0.3, 1.2)
Type of symptoms:
Breast mass versus other ﬁrst symptom:
2.1 (0.9, 4.8)
*Adjusted for age, residential status,
and education
Delay from ﬁrst medical consultation to
arrival at TTC >2 wk: OR (95% CI)
Socioeconomic:
Aged 50 versus < 50 y: 0.6 (0.3, 1.2)
Urban versus rural residence: 0.8 (0.4, 1.5)
Bachelor versus<bachelor education: 1.2 (0.7,
2.3)
Type of symptoms:
Breast mass versus other ﬁrst symptom: 0.8
(0.4, 1.8)
Health serviceserelated:
First health care provider versus TCC:
Primary care: 11.0 (2.9, 41.7)
Gynecologist: 9.0 (1.6, 52.3)
Medical oncologist: 5.6 (1.0, 30.9)
General surgeon: 5.5 (1.7, 18.0)
Surgical oncologist: 3.0 (0.7, 13.4)
Delay from ﬁrst medical consultation to arrival at
TTC >2 wk: OR* (95% CI)
Socioeconomic:
Aged 50 versus < 50 y: 0.6 (0.3, 1.4)
Urban versus rural residence: 1.1 (0.5, 2.3)
Bachelor versus <bachelor education: 1.3 (0.5,
2.9)
Type of symptoms:
Breast mass versus other ﬁrst symptom: 1.3 (0.6,
3.1)
Health serviceserelated:
First HCP versus TCC:
Primary care: 12.2 (2.9, 51.0)
Gynecologist: 8.6 (1.4, 53.4)
Medical oncologist: 8.3 (1.3, 55.0)
General surgeon: 7.6 (2.1, 27.6)
Surgical oncologist: 3.4 (0.7, 16.0)
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Other: 12.0 (2.2, 66.5)
Navigation pathway versus directly to TCC:
General surgeon/ Surgical oncologist/ TCC:
29.3 (4.6, 184.4)
General surgeon/ Medical oncologist/ TCC:
6.0 (0.9, 38.1)
Primary care/ Others/ TCC: 19.5 (3.7, 102.4)
Other: 11.0 (1.9, 63.3)
Navigation pathway versus directly to TCC:
General surgeon/ Surgical oncologist/ TCC: 35.4
(5.3, 237.5)
General surgeon/ Medical oncologist/ TCC: 8.1
(1.0, 62.2)
Primary care/ Others/ TCC: 23.2 (4.0, 134.5)
*Adjusted for age, residential status, education level,
tumor stage, and ﬁrst symptom
Stapleton, 2011 [9]
(Egypt)
Late versus early stage at diagnosis: Mutually adjusted OR (95% CI)
>33 wk versus 33 delay in seeking treatment: 1.57 (0.76, 3.23)
Financial and other constraints
Social, ﬁnancial, and time constrains versus no delay:
1.72 (0.86, 3.46)
Type of symptoms:
No pain versus no delay: 2.68 (1.18, 6.08)
BC awareness:
Knowledge of BSE versus no knowledge:
0.24 (0.06, 0.94)
Previous CBE versus no previous CBE: 1.00 (0.28, 3.62)
Previous mammogram versus no previous mammogram:
2.17 (0.48, 9.72)
Health services related:
Site of treatment NCI-Cairo versus TCC:
5.05 (1.30, 19.70)
Visited versus not visited a second provider:
0.72 (0.30, 1.74)
First diagnosed versus not ﬁrst diagnosed as
BC: 0.99 (0.52, 1.89)
Referral versus no referral: 1.10 (0.57, 2.12)
Treated in a hospital versus present facility:
0.80 (0.43, 1.48)
Travel time to facility >1 h versus 1 h: 1.64 (0.96, 2.79)
Sub-Saharan Africa
Clegg-Lamptey, 2009
[18] (Ghana)
Reasons for delay from symptoms recognition to presentation at the study hospital where
diagnosis was made (%)
Lack of BC awareness: 28.8%
Fear of diagnosis or mastectomy: 34.8%
Tried traditional/alternative treatments: 19.7%
Tried spiritual cures: 19.7%
Financial problems: 18.2%
Lack of knowledge of BSE: 57.6%
Other: 4.5%
Health services related:
Previous medical consultation: 39.4%
Previous hospital consultations at a different hospital:
72.7%, with diagnosis made in only 52% of these
Ezeome, 2010 [19]
(Nigeria)
Reasons for delay between symptoms
recognition
and visit to ﬁrst HCP
Symptom(s) not serious/hoping they
will resolve: 27.8%
Lack of BC awareness: 23.3%
Tried traditional/spiritual treatments:
12.6%
Financial problems: 13.9%
Painless: 12%
Fear/refusal of mastectomy: 5.6%
Family/social problems: 5.6%
n/a Reasons for delay between symptoms
recognition and start of BC treatment
Patient-related
Lack of BC awareness: 25.3%
Finance: 16.9%
Thought it was harmless/will disappear: 15.4%
Fear/refused surgery/mastectomy: 9.2%
Painless/not disturbing her: 6.9%
Delayed by family/social problems: 6.9%
Traditional/spiritual treatments: 5.4%
Discouraged by friends/relatives: 5.4%
Health care providererelated:
n/a
(continued on next page)
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Appendix C (continued )
Author, year [ref no]
(country)
Factors associated with delay between symptoms recognition and ﬁrst visit to an
HCP
Factors associated with delay between ﬁrst visit to an HCP and BC diagnosis or start of treatment
Crude Adjusted Crude Adjusted
Though it was pregnancy/lactation
effect: 3.2%
Discouraged by friends/relatives: 3.2%
Others: 15.7%
Delayed referrals or nonreferrals: 17.8%
Wrong advice and false reassurance by health
professionals: 11.5%
Delayed histology report: 6.2%
No histology after biopsy: 5.4%
Industrial actions: 4.6%
Ibrahim, 2012 [20]
(Nigeria)
Delay from symptoms recognition to
ﬁrst
medical consultation >3 mo
Reasons given:
Lack of BC awareness: 34.1%
Belief in spiritual healing: 32.3%
Fear of mastectomy: 29.3%
Belief in herbal treatment: 22%
Belief in alternative therapy: 7.3%
Lack of funds: 3%
Reassurance by nonmedical health
worker: 3%
Crude analysis:
Being single: OR ¼ 2.05, 95% CI: 0.25,
16.8
Primary level of education: OR ¼ 3.06,
95%
CI: 0.96, 9.73
Negative history of benign breast
disease:
OR ¼ 1.65, 95% CI: 0.76, 3.59
Delay from symptoms recognition to
ﬁrst medical
consultation >3 mo
“In the multivariate analysis, being
premenopausal
(OR ¼ 1.86; 95% CI, 0.38, 9.4) was the
additional factor
associated with increased risk of late
presentation” (sic)
n/a n/a
Marcus, 2013 [21],y
(South Africa)
Delay from ﬁrst symptoms to
presentation
>6 mo versus 3e6 mo: OR (95% CI)
Socioeconomic:
Age (vs. 34e45 [sic]):
45e54: 0.15
55e64: 0.18
65e83: 0.77
Education (vs. none):
Primary: 0.41
Secondary or higher: 0.18
Employed versus unemployed: 0.26
Married versus single/divorced/
widowed: 0.31
BC awareness:
Previous cancer diagnosis: 0
Delay from ﬁrst symptoms to
presentation >6 mo
versus 3e6 mo: Adjusted* OR (95% CI)
Socioeconomic:
Age (vs. 34e45 [sic]):
45e54: 2.05
55e64: 2.55 (P < .05)
65e83: 2.28
Education (vs. none):
Primary: 0.27
Secondary or higher: 1.56
Employed versus unemployed: 0.63
Married versus single/divorced/
widowed: 0.84
BC awareness:
Previous cancer diagnosis: 22.13 (P <
.01)
*for all variables in the model
n/a n/a
Otieno, 2010 [22],y
(Kenya)
Reasons for delays from ﬁrst symptoms to presentation at diagnostic
hospital, i.e., to diagnosis
Lack of BC awareness: 7.8%
Painless symptom(s): 23.5%
Fear of cancer: 19.9%
Symptoms considered benign by health professionals: 24.1%
Tried traditional treatments: 9.6%
Others: 15.1%
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Pace, 2015 [23]
(Rwanda)
Reasons for delay between ﬁrst
symptoms to
ﬁrst visit to an HCP (%)
Did not think it was a problem at ﬁrst:
76%
Thought it would go away: 63%
Visited traditional healer ﬁrst: 21%
Thought treatment was too expensive:
14%
Too busy at home or job: 7%
Fear of cancer: 6%
Afraid of treatment and mastectomy:
5%
Reasons for delay between ﬁrst
symptoms to ﬁrst
visit to an HCP: OR* (95% CI) for delay
>6 versus <6 mo
Socioeconomic:
Age (y) versus <40 y:
40e49: 2.26 (0.69, 7.43)
50e59: 1.22 (0.36, 4.11)
>60: 2.30 (0.60, 8.74)
Married versus unmarried: 1.11 (0.51,
2.48)
No education/primary school versus
secondary/university:
4.88 (1.72, 13.88)
Reproductive:
Breastfeeding (yes vs. no): 2.09 (0.44,
9.87)
BC awareness:
BC family history (yes vs. no): 0.53
(0.14, 2.04)
Ever done BSE (yes vs. no): 0.73 (0.31,
1.74)
Ever heard of BC (yes vs. no): 1.86 (0.69,
5.00)
Type of symptoms and comorbidities:
Breast pain as initial symptom (yes vs.
no): 0.57 (0.25, 1.30)
HIV or other comorbidities (yes vs. no/
unknown): 1.15 (0.43, 3.07)
Alternative treatments:
Saw traditional healer ﬁrst: 4.26 (1.56,
11.60)
Health services related:
Travel time to HCP (>2 vs. 2 h): 0.96
(0.36, 2.57)
Regular CHW visits (yes vs. no): 1.51
(0.66, 3.46)
*Mutually adjusted for all variables in
the model
Reasons for delay between ﬁrst visit to an
HCP and date of pathology report conﬁrming
BC (%)
Nonreferral from another health care center:
69%
Did not know this cancer existed: 30%
Did transfer from another health facility: 27%
Too expensive to travel from home to hospital:
21%
Told by a health care provider, there was no
cure: 3%
Hospital too far to travel to: 2%
Reasons for delay between ﬁrst visit to an HCP
and date of pathology report conﬁrming BC
OR* (95% CI) for delay ‡6 versus 6 mo
Socioeconomic:
Age (y) versus <40 y:
40e49: 0.57 (0.20, 1.68)
50e59: 0.85 (0.28, 2.62)
>60: 0.64 (0.18, 2.24)
Married versus unmarried: 1.11 (0.51, 2.41)
No education/primary school versus secondary/
university: 1.19 (0.48, 2.97)
Reproductive:
Breastfeeding (yes vs. no): 0.81 (0.15, 4.30)
BC awareness:
BC family history (yes vs. no): 0.60 (0.15, 2.34)
Ever done BSE (yes vs. no): 1.15 (0.50, 2.65)
Ever heard of BC (yes vs. no): 1.19 (0.45, 3.10)
Type of symptoms and comorbidities:
Breast pain as initial symptom (yes vs. no): 1.15
(0.52, 2.55)
HIV or other comorbidities (yes vs. no/unknown):
0.84 (0.32, 2.17)
Health services related:
Travel time to an HCP (>2 vs.2 h): 1.26 (0.46, 3.42)
Regular CHW visits (yes vs. no): 1.14 (0.50, 2.58)
No. of visits to other health care facilities before
diagnosis (<5 vs. 5): 2.69 (1.24, 5.84)
Referred by (vs. health center):
District hospital: 0.51 (0.09, 2.78)
Private hospital: 0.36 (0.06, 2.09)
Unknown: 0.49 (0.07, 3.45)
*Mutually adjusted for all variables in the model
Price, 2012 [24]
(Cameroon)
Financial problems: 16%
Spent >$10 on one-way transportation: 42%
Traveled >4 h to hospital: 46%
n/a
Toure, 2013 [25]
(Côte d’Ivoire)
Reasons for delay between symptoms recognition and date of histological
conﬁrmation
Crude OR (95% CI) for delay > 6 mo
Initial symptom (vs. nodule)
Inﬂammation: 23.6 (7.5, 74.0)
Ulcer: 18.1 (4.3, 76.9)
Nipple discharge: 1.9 (0.6, 6.2)
Metastases: 13.9 (3.3, 59.3)
Self-reported reason for delay (vs. having ﬁnancial problems)
Traditional medicine: 0.5 (0.2, 1.2)
Fear of cancer: 0.4 (0.1, 2.3)
Misdiagnosis: 1.8 (0.2, 15.3)
Inadequate medical care: 1.1 (0.2, 5.4)
Monthly income in euros (vs. none):
<91.46: 1.4 (0.5, 3.6)
91.46e182.8: 0.8 (0.3, 2.1)
182.9e274.4: 0.8 (0.3, 2.3)
>274.4: 3.2 (0.4, 25.9)
Mutually adjusted OR (95% CI) for delay >6 mo (having ﬁnancial problems taken as the reference
category)
Self-reported reason for delay (vs. having ﬁnancial problems)
Traditional medicine: 0.7 (0.7, 3.2)
Fear of cancer: 1.2 (0.0, 12.3)
Misdiagnosis: 3.0 (0.3, 5.7)
Inadequate medical care: 0.6 (0.1, 17.4)
Monthly income in euros (vs. none):
<91.46: 0.3 (0.0, 1.7)
91.46e182.8: 4.4 (0.2, 91.2)
182.9e274.4: 12.7 (0.4, 376.6)
>274.4: 47.8 (0.7, 3.103 [sic])
(continued on next page)
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Appendix C (continued )
Author, year [ref no]
(country)
Factors associated with delay between symptoms recognition and ﬁrst visit to an
HCP
Factors associated with delay between ﬁrst visit to an HCP and BC diagnosis or start of treatment
Crude Adjusted Crude Adjusted
Quantitative and qualitative studies
Dye, 2010 [26]
(Ethiopia)
Reasons for delays between symptom recognition and presentation
at diagnostic center (TA)
Lack of BC awareness
Health services:
High travel distance
Too expensive
>3 HCP visits: 73.2%
First HCP: % of patients (Me  SE number of care nodes
visited including study setting [TAH]):
Primary care: 53.7% (3.3  1.8)
Traditional healer: 16.4% (3.8  0.26)
Local/regional hospital: 16.4% (2.3  0.19)
Private hospital: 9% (2.8  0.48)
TAH: 4.5%
Ly, 2002 [27] (Mali) Reasons for delays between symptom recognition and presentation at ﬁrst HCP
Symptom(s) not serious: 82%
Caused by witchcraft: 14%
n/a
Qualitative studies
Ekortarl, 2007 [28]
(Cameroon)
Reasons for delays between symptom recognition and
presentation at ﬁrst HCP
Ignorance and beliefs
Fears
Financial problems
Inadequate diagnosis by general doctors
Mbuka-Ongona, 2012
[29] (Botswana)
Reasons for delays between symptom recognition and
visit to diagnostic center
Lack of BC awareness
Misinterpretation of signs
Infrequent BSE
Fear of diagnosis and death
Inﬂuence of traditional healers
Health services:
Poor clinical practices of health workers
Overemphasis on HIV infection
Long travel distance to hospital
Pruitt, 2015 [30]
(Nigeria)
Reasons for delays between symptom recognition
and ﬁrst visit to an HCP
Lack of BC awareness
Symptom(s) not serious
Tried traditional and spiritual treatments
Reasons for delays between presentation and diagnosis and treatment
Inappropriate medical care given
Delays in getting diagnostic conﬁrmation or treatment
Return to traditional care
Denial
Fear of surgery
Strikes by hospital staff
Treatment costs
BC ¼ breast cancer; BSE ¼ breast self-examination; CBE ¼ clinical breast examination; CHW ¼ community health worker; CI ¼ conﬁdence interval; HCP ¼ health care provider; HIV ¼ human immunodeﬁciency virus; IQR ¼
interquartile range; km¼ kilometers; LABC¼ locally advanced breast cancer; Md¼mean; Me¼mean; n/a¼ not reported in the original publication; OC¼ oral contraceptives; OR¼ odds ratio; Ra¼ range; SE ¼ standard error;
TAH ¼ Tikur Anbessa Hospital; TCC ¼ Tanca Cancer Center.
Bold values are statistically signiﬁcant.
y Study recruited only patients with advanced breast cancer (see Table 1).
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